Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 14/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25848879 | 0.90 | EPHX2 (0.49) | HDAC1HDAC6EPHX2LMNAMAPK1 | |
| SCHEMBL30393345 | 0.90 | EPHX2 (0.49) | HDAC1HDAC6EPHX2LMNAMAPK1 | |
| SCHEMBL25848762 | 0.88 | HDAC1 (0.46) | HDAC1HDAC6EPHX2HPGDRAB9A | |
| SCHEMBL25848772 | 0.88 | NPC1 (0.43) | EPHX2RAB9A | |
| SCHEMBL25848789 | 0.87 | HDAC1 (0.45) | HDAC1HDAC6EPHX2HPGDRAB9A | |
| SCHEMBL25848767 | 0.87 | KMT2A (0.35) | HDAC1HDAC6 | |
| SCHEMBL25848768 | 0.86 | KMT2A (0.39) | HDAC1HDAC6HPGDRAB9ALMNA | |
| SCHEMBL25848773 | 0.86 | P2RX7 (0.41) | HDAC1HDAC6EPHX2HPGDNR1H4 | |
| SCHEMBL25848776 | 0.84 | EPHX2 (0.42) | HDAC1HDAC6EPHX2PPARG | |
| SCHEMBL25848766 | 0.84 | RXFP1 (0.47) | EPHX2HPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219921-A1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219921-A1 | KCNT1 INHIBITORS AND METHODS OF USE | KCNT1, KCNT2, KCNQ2 | HDAC1 1680/4885HDAC6 1167/4885EPHX2 2590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.